Deutsche Bank analyst Pito Chickering raised the firm’s price target on Quest Diagnostics (DGX) to $178 from $160 and keeps a Hold rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics: Strong Financial Outlook and Strategic Positioning Justify Buy Rating
- Quest Diagnostics: Strong Performance and Growth Potential Justify Buy Rating
- Quest Diagnostics Reports Strong Q2 2025 Results
- Quest Diagnostics Reports Strong Growth in Earnings Call
- Morning Movers: Lockheed Martin slips following second quarter report